Alarin Level Response to an Oral Glucose Tolerance Test in Subjects with Gestational Diabetes Mellitus

Alarin has been reported to ameliorate insulin resistance in type 2 diabetis mellitus. However, until now, there is no report examined the relationship between alarin and gestational diabetes mellitus (GDM). Therefore, the purpose of this study is to examine the level of alarin in subjects with and without gestational diabetes mellitus. 30 healthy and 30 gestational diabetes mellitus subjects were recruited for this study. A 2-hour 75 g oral glucose tolerance test (OGTT) was performed at 24–28 weeks of pregnancy. GDM were diagnosed using nationally endorsed criteria (fasting [FPG], 1- or 2-hour blood glucose [at least one abnormal value]. Plasma alarin level was measured by ELISA. Plasma alarin levels were significantly higher GDM subjects than in healthy individuals (12. 3±1.4 ng/mL vs 7.8±0.8 ng/mL; p < .05).1- (18. 8±1.9 ng/mL) and 2-hour (24. 2±3.1 ng/mL) alarin levels in women with GDM were significantly increased at OGTT compared with women without GDM [1- (9.4±0.9 ng/mL); 2- (9.7±0.6 ng/mL)]. Plasma alarin positively correlated with FBG, HbA1c, HOMA-IR and insulin). The above results suggest that alarin might be associated in the pathogenesis of gestational diabetes mellitus.